TODDLER COVID RASH SKIN

1, 2 Despite a relatively benign clinical course for most, pediatric patients may rarely exhibit exaggerated immune responses that fall on a spectrum ranging from a mild febrile inflammatory state without multisystem involvement, to a moderate Kawasaki disease (KD)–like illness, to a severe multisystem inflammatory syndrome with shock. This was likely due to the disproportionately lower rates at which children are affected by COVID-19 compared with adults, in terms of both infection rates and severity of clinical manifestations. More thorough descriptions of dermatologic manifestations in patients with MIS-C are warranted to better characterize this syndrome, as they may lend important insight into pathogenic mechanisms of disease.Īt the outset of the novel coronavirus disease 2019 (COVID-19) pandemic, it was thought that children were generally unaffected by the deadly viral infection rapidly sweeping across the globe. Case reports and smaller case series provided more detail, outlining a broad range of lesion morphologies (polymorphic, maculopapular, morbilliform, erythrodermic, urticarial, reticular, petechial, purpuric) in variable anatomic distribution.

TODDLER COVID RASH SKIN

“Rash” was the sole descriptor of skin findings in nearly half of patients. In this retrospective review of 34 case reports and series, we identified cutaneous manifestations documented in 417 of 736 patients (57%) with MIS-C associated with COVID-19. Skin findings are often present in these patients, and when initially compared with Kawasaki disease, they likely represent distinct phenomena and overall remain poorly characterized. Multisystem inflammatory syndrome in children (MIS-C) affects a small percentage of pediatric patients infected with COVID-19 and is characterized by fever, laboratory evidence of inflammation, multisystem involvement, and severe illness necessitating hospitalization.

Toddler covid rash